

IFW

Date: June 30, 2004

I hereby certify that, on the date indicated above, I deposited this paper with identified attachments and/or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 by "First Class Mail" service.

Donald S. Prater

Name (Print)

Donald S. Prater
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: HELLBERG et al.)	Examiner: Unassigned
)	
Application No.: 10/723,208)	Group Art Unit: 1614
)	
Filed: November 26, 2003)	Confirmation No.: 8524
)	
Docket No.: 2162 (3010-009-01))	Customer No.: 33432

For: NOVEL ARYLAMINOPROPANE ANALOGUES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97(b)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

June 30, 2004

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. Since this application has a filing date after June 30, 2003, no copies of U.S. Patents/Patent Application Publications are provided. One copy of each foreign publication and "other" documents are attached.

This Information Disclosure Statement is being submitted after expiration of the three-month period following filing of the above-captioned application, but before an Office Action on the merits and before any final Office Action or Notice of Allowance.

Should a first Office Action cross in the mail with the filing of this Information Disclosure statement, then the applicants respectfully petition under 37 C.F.R. §1.97(c) to consider the documents set forth in the Information Disclosure Statement.

The above information is presented so that the Patent and Trademark Office can, in the first

Information Disclosure Statement
U.S. Patent Application No. 10/723,208


instance, determine any materiality thereof to the claimed invention. *See* 37 C.F.R. §§1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-1449 be made of record therein and appear on the first page of any patent to issue therefrom.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in this application and the applicants determine that the cited documents do not constitute "prior art" under United States law, the applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


It is believed that no fee is required to make this a complete and timely filing. However, if it is determined that a petition or fee is required, the Commissioner is hereby authorized to charge any fee associated with this statement to our Deposit Account No. 50-0925 and please consider this a petition.

Respectfully submitted,



Luke A. Kilyk
Reg. No. 33,251

Atty. Docket No.: 2162 (3010-009-01)
KILYK & BOWERSOX, P.L.L.C.
53 A East Lee Street
Warrenton, VA 20186
Tel.: (540) 428-1701
Fax: (540) 428-1720
Enclosures: PTO-1449, w/26 Documents




FORM PTO-1449 (REV 7-80)		Atty. Docket No. 2162 (3010-009-01)	Application No. 10/723,208
INFORMATION DISCLOSURE STATEMENT		APPLICANT: Hellberg et al.	
		Filing Date: November 26, 2003	Group Art Unit: 1614

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE, IF APPROPRIATE
	A	5,578,612	11/26/96	Macor et al.	514	323	
	B	5,494,928	2/27/96	Bös	514	415	
	C	5,571,833	11/5/96	Kruse et al.	514	414	
	D	5,874,477	2/23/99	McConnell et al.	514	657	
	E	5,902,815	5/11/99	Olney et al.	514	285	
	F	5,889,052	3/30/99	Klimko et al.	514	530	
	G	5,296,504	3/22/94	Stjerschantz et al.	514	530	
	H	5,422,368	6/6/95	Sternschantz et al.	514	530	
	I	5,151,444	9/29/92	Ueno et al.	514	530	
	J	5,352,708	10/4/94	Woodward et al.	514	729	
	K	4,690,931	9/1/87	Wick et al.	514	317	
	L	6,548,493 B1	4/15/03	Robichaud et al.	514	212.05	
	M	6,552,017 B1	4/22/03	Robichaud et al.	514	219	
	N	6,713,471 B1	3/30/04	Robichaud et al.	514	211.1	
	O	US 2004/ 0034015 A1	2/19/04	Robichaud et al.	514	219	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	NO
	P	WO 98/18458	5/7/98	WIPO				
	Q	WO 92/20338	11/26/92	WIPO				
	R	WO 97/33579	9/17/97	WIPO				
	S	WO 98/31354	7/23/98	WIPO				
	T	WO 00/12475	3/9/00	WIPO				
	U	WO 00/12510	3/9/00	WIPO				
	V	WO 00/44753	8/3/00	WIPO				
	W	WO 00/35922	6/22/00	WIPO				
	X	WO 94/13275	6/23/94	WIPO				
	Y	WO 00/16761	3/30/00	WIPO				



	Z	EP 0771563 A2	5/7/97	EPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Ichiro et al., "Studies on the synthesis of 2-substituted-1-naphthols and 7-substituted-8-quinolinols," <i>Chem. Abstr.</i> Vol. 108, 186616g, pp. 695 (1988)
	Horii et al., "Synthetic Studies on Anthracyclines. IX Lithiation of N,N-Dimethyl-naphthalenemethylamines and a New Synthetic Pathway to 2,3-Naphthalides," <i>Chem. Pharma. Bull.</i> Vo. 19(6), pp. 1245-1256 (1971)
	IOVS, <i>Aqueous Humor Dynamics I</i> , Vol. 39(4), S488, 2236-B93, (1998)
	Glennon, et al., "Binding of Substituted and Conformationally Restricted Derivatives of N-(3-Phenyl-n-propyl)-1-phenyl-2-aminopropane at σ -Receptors," <i>J. Med. Chem.</i> Vol. 34, pp. 1855-1859 (1991)
	R. Howe, " β -Adrenergic Blocking Agents. VI, Pronethalol and Propranolol Analogs with Alkyl Substituents in the Alkanol Side Chain," <i>J. Med. Chem.</i> Vol. 12, pp. 642-646 (1969)
	Govindachari et al., "Synthesis of 3-Methyl Isoquinolines," <i>J. Org. Chem.</i> Vol. 18, pp. 1253-1262 (1953)
	Griffin, et al., "Pharmacological Characterization of an FP Prostaglandin Receptor on Rat Vascular Smooth Muscle Cells (A7r5) Coupled to Phosphoinositide Turnover and Intracellular Calcium Mobilization," <i>J. Pharmacol. Expt. Ther.</i> Vol. 286, pp. 411-418 (1998)
	Johnson et al., "Binding to the Serotonin 5-HT ₂ Receptor by the Enantiomers of 125I-DOI," <i>Neuropharmacology</i> , Vol. 26, No. 12, pp. 1803-1806 (1987)
	Osborne, et al. "Do Beta-Adrenoceptors and Serotonin 5-HT _{1A} Receptors Have Similar Functions in the Control of Intraocular Pressure in the Rabbit?" <i>Ophthalmologica</i> , Vol. 210, pp. 308-314 (1996)
	Fiorella, "Role of 5-HT _{2A} and 5-HT _{2C} receptors in the stimulus effects of hallucinogenic drugs II: reassessment of LSD false positives," <i>Psychopharmacology</i> , Vol. 121:357-363, 1995
	Bowen et al., "Nonlinear regression using spreadsheets," <i>Trends Pharmacol. Sci.</i> , Vol. 16, pp. 413-417 (1995)
	Wang, et al., "Effect of 5-methylurapidil, an α_{1A} -adrenergic antagonist and 5-hydroxytryptamine _{1A} agonist, on aqueous humor dynamics in monkeys and rabbits" <i>Current Eye Research</i> , Vol. 16(8) pp. 769-775 (1997)
	Nabih, et al., "Synthesis of (Heterocyclicamino) aminoalkylnaphthols and Reduced Tetrahydro Derivatives for Possible Antimalarial Activity," <i>J. of Pharm. Sciences</i> , Vol. 61, No. 9, pp. 1500-1501 (1972)
	Clare, "The Frontier Orbital Phase Angles: Novel QSAR Descriptors for Benzene Derivatives, Applied to phenylalkylamine Hallucinogens," <i>J. Med. Chem.</i> Vol. 41, pp. 3845-3856 (1998)
	International Search Report for PCT/US02/16842 dated August 19, 2002

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.